High mobility group box 1 (HMGB1) mediates high-glucose-induced calcification in vascular smooth muscle cells of saphenous veins

Inflammation

Volumn 36, Issue 6, 2013, Pages 1592-1604

  Wang, Yongyi ^a   Shan, Jianggui ^a   Yang, Wengang ^a   Zheng, Hui ^a   Xue, Song ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

calcification; high glucose; high mobility group box 1; saphenous vein graft; vascular smooth muscle cell

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BONE MORPHOGENETIC PROTEIN 2; GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ARTICLE; BLOOD VESSEL CALCIFICATION; CELL CULTURE; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CYTOSOL; DOWN REGULATION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SAPHENOUS VEIN CALCIFICATION; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE; VEIN DISEASE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTIGENS, NEOPLASM; BONE MORPHOGENETIC PROTEIN 2; CELLS, CULTURED; CORONARY ARTERY BYPASS; DIABETES MELLITUS; ENZYME ACTIVATION; GLUCOSE; HMGB1 PROTEIN; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; NF-KAPPA B; PROMOTER REGIONS, GENETIC; SAPHENOUS VEIN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; VASCULAR CALCIFICATION;

EID: 84888206020     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9704-1     Document Type: Article

References (41)

1. Wittlinger, T., I. Martinovic, F. Bakhtiary, F. Oezaslan, A. Moritz, and K. Ehrhard. 2006. Detection of vein graft disease using 4-row computed tomography. Evaluation of coronary bypass graft patency and correlation with the Ca-score. The Journal of Thoracic and Cardiovascular Surgery 54: 96-101.
2. Peykar, S., D.J. Angiolillo, T.A. Bass, and M.A. Costa. 2004. Saphenous vein graft disease. Minerva Cardioangiologica 52: 379-390.
3. Castagna, M.T., G.S. Mintz, P. Ohlmann, J. Kotani, A. Maehara, N. Gevorkian, E. Cheneau, E. Stabile, A.E. Ajani, W.O. Suddath, K.M. Kent, L.F. Satler, A.D. Pichard, and N.J. Weissman. 2005. Incidence, location, magnitude, and clinical correlates of saphenous vein graft calcification: An intravascular ultrasound and angiographic study. Circulation 111: 1148-1152.
4. Ndip, A., A. Williams, E.B. Jude, F. Serracino-Inglott, S. Richardson, J.V. Smyth, A.J. Boulton, and M.Y. Alexander. 2011. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 60: 2187-2196.
5. Johnson, R.C., J.A. Leopold, and J. Loscalzo. 2006. Vascular calcification: pathobiological mechanisms and clinical implications. Circulation Research 99: 1044-1059.
6. Chen, N.X., D. Duan, K.D. O'Neill, and S.M. Moe. 2006. High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrology, Dialysis, Transplantation 21: 3435-3442.
7. Liu, F., H. Zhong, J.Y. Liang, P. Fu, Z.J. Luo, L. Zhou, R. Gou, and J. Huang. 2010. Effect of high glucose levels on the calcification of vascular smooth muscle cells by inducing osteoblastic differentiation and intracellular calcium deposition via BMP-2/Cbfα-1 pathway. Journal of Zhejiang University. Science. B 11: 905-911.
8. Hsieh, M.S., W.B. Zhong, S.C. Yu, J.Y. Lin, W.M. Chi, and H.M. Lee. 2010. Dipyridamole suppresses high glucose-induced osteopontin secretion and mRNA expression in rat aortic smooth muscle cells. Circulation Journal 74: 1242-1250.
9. New, S.E., and E. Aikawa. 2011. Cardiovascular calcification: an inflammatory disease. Circulation Journal 75: 1305-1313.
10. Dasu, M.R., S. Devaraj, L. Zhao, D.H. Hwang, and I. Jialal. 2008. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 57: 3090-3098.
11. Thornalley, P.J. 2007. Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE) - An introduction. Molecular Nutrition & Food Research 51: 1107-1110.
12. Heizmann, C.W. 2007. The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: Arguing against the motion. Molecular Nutrition & Food Research 51: 1116-1119.
13. Naruse, K., T. Sado, T. Noguchi, T. Tsunemi, S. Yoshida, J. Akasaka, N. Koike, H. Oi, and H. Kobayashi. 2012. Peripheral RAGE (receptor for advanced glycation endproducts)-ligands in normal pregnancy and preeclampsia: Novel markers of inflammatory response. Journal of Reproductive Immunology 93: 69-74.
14. Cai, X.Y., L. Lu, Y.N. Wang, C. Jin, R.Y. Zhang, Q. Zhang, Q.J. Chen, and W.F. Shen. 2011. Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury. Atherosclerosis 217: 536-542.
15. Hofmann Bowman, M.A., J. Gawdzik, U. Bukhari, A.N. Husain, P.T. Toth, G. Kim, J. Earley, and E.M. McNally. 2011. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arteriosclerosis, Thrombosis, and Vascular Biology 31: 337-344.
16. Harris, H.E., U. Andersson, and D.S. Pisetsky. 2012. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nature Review Rheumatology 8: 195-202.
17. Sims, G.P., D.C. Rowe, S.T. Rietdijk, R. Herbst, and A.J. Coyle. 2010. HMGB1 and RAGE in inflammation and cancer. Annual Review of Immunology 28: 367-388.
18. 2, and high intravascular pressure. Circulation 111: 2364-2372.
19. Lee, T.S., K.A. Saltsman, H. Ohashi, and G.L. King. 1989. Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications. Proceedings of the National Academy of Sciences of the United States of America 86: 5141-5.
20. Inoguchi, T., P. Li, F. Umeda, H.Y. Yu, M. Kakimoto, M. Imamura, T. Aoki, T. Etoh, T. Hashimoto, M. Naruse, H. Sano, H. Utsumi, and H. Nawata. 2000. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49: 1939-45.
21. Peters, K.R. 2011. Intensifying treatment of type 2 diabetes mellitus: Adding insulin. Pharmacotherapy 31(12 Suppl): 54S-64S.
22. Nelson, S.E., and P.J. Palumbo. 2006. Addition of insulin to oral therapy in patients with type 2. Diabetes 331: 257-263.
23. Tanenberg, R.J. 2004. Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes. Current Medical Research and Opinion 20: 541-553.
24. Towler, D.A. 2011. Vascular calcification: It's all the RAGE! Arteriosclerosis, Thrombosis, and Vascular Biology 31: 237-239.
25. Gawdzik, J., L. Mathew, G. Kim, T.S. Puri, and M.A. Hofmann Bowman. 2011. Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. American Journal of Nephrology 33: 250-259.
26. Yao, D., and M. Brownlee. 2010. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59: 249-255.
27. Soro-Paavonen, A.M. Watson, J. Li, K. Paavonen, A. Koitka, A.C. Calkin, D. Barit, M.T. Coughlan, B.G. Drew, G.I. Lancaster, M. Thomas, J.M. Forbes, P.P. Nawroth, A. Bierhaus, M.E. Cooper, and K.A. Jandeleit-Dahm. 2008. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57: 2461-2469.
28. López, J., I. Fernández-Pisonero, A.I. Dueñas, P. Maeso, J.A. Román, M.S. Crespo, and C. García-Rodríguez. 2012. Viral and bacterial patterns induce TLR-mediated sustained inflammation and calcification in aortic valve interstitial cells. International Journal of Cardiology 158: 18-25.
29. Su, X., L. Ao, Y. Shi, T.R. Johnson, D.A. Fullerton, and X. Meng. 2011. Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4. The Journal of Biology Chemistry 286: 12213-12220.
30. Zhao, M.M., M.J. Xu, Y. Cai, G. Zhao, Y. Guan, W. Kong, C. Tang, and X. Wang. 2011. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney International 79: 1071-1079.
31. Volz, H.C., C. Seidel, D. Laohachewin, Z. Kaya, O.J. Müller, S.T. Pleger, F. Lasitschka, M.E. Bianchi, A. Remppis, A. Bierhaus, H.A. Katus, and M. Andrassy. 2010. HMGB1: The missing link between diabetes mellitus and heart failure. Basic Research in Cardiology 105: 805-820.
32. Hattori, Y., S. Hattori, N. Sato, and K. Kasai. 2000. High-glucose-induced nuclear factor kappaB activation in vascular smooth muscle cells. Cardiovascular Research 46: 188-197.
33. Kim, Y.S., J.S. Kim, J.S. Kwon, M.H. Jeong, J.G. Cho, J.C. Park, J.C. Kang, and Y. Ahn. 2010. BAY 11-7082, a nuclear factor-κB inhibitor, reduces inflammation and apoptosis in a rat cardiac ischemia-reperfusion injury model. International Heart Journal 51: 348-353.
34. Tranter, M., X. Ren, T. Forde, M.E. Wilhide, J. Chen, M.A. Sartor, M. Medvedovic, and W.K. Jones. 2010. NF-kappaB driven cardioprotective gene programs; Hsp70.3 and cardioprotection after late ischemic preconditioning. Journal of Molecular and Cellular Cardiology 49: 664-72.
35. Xuan, Y.T., X.L. Tang, S. Banerjee, H. Takano, R.C. Li, H. Han, Y. Qiu, J.J. Li, and R. Bolli. 1999. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circulation Research 84: 1095-109.
36. Feng, J.Q., L. Xing, J.H. Zhang, M. Zhao, D. Horn, J. Chan, B.F. Boyce, S.E. Harris, G.R. Mundy, and D. Chen. 2003. NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. The Journal of Biology Chemistry 278: 29130-29135.
37. Li, X., and X.Z. Bai. 2008. NF-kappaB modulates activation of the BMP-2 gene by trichostatin A. Molecular Biology (Mosk) 42: 990-996.
38. Graham, T.R., V.A. Odero-Marah, L.W. Chung, K.C. Agrawal, R. Davis, and A.B. Abdel-Mageed. 2009. PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-kappaB in metastatic prostate cancer cells. Prostate 69: 168-180.
39. Eliseev, R.A., E.M. Schwarz, M.J. Zuscik, R.J. O'Keefe, H. Drissi, and R.N. Rosier. 2006. Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFkappaB. Experimental Cell Research 312: 40-50.
40. Ren, X.Y., Q.R. Ruan, D.H. Zhu, M. Zhu, Z.L. Qu, and J. Lu. 2007. Tetramethylpyrazine inhibits angiotensin II-induced nuclear factor-kappaB activation and bone morphogenetic protein-2 downregulation in rat vascular smooth muscle cells. Sheng Li Xue Bao 59: 339-344.
41. Zhang, R., J.R. Edwards, S.Y. Ko, S. Dong, H. Liu, B.O. Oyajobi, C. Papasian, H.W. Deng, and M. Zhao. 2011. Transcriptional regulation of BMP2 expression by the PTH-CREB signaling pathway in osteoblasts. PLoS One 6: e20780.